MX9803898A - Metodo y mejorado y agentes para inhibir el envejecimiento de proteina. - Google Patents

Metodo y mejorado y agentes para inhibir el envejecimiento de proteina.

Info

Publication number
MX9803898A
MX9803898A MX9803898A MX9803898A MX9803898A MX 9803898 A MX9803898 A MX 9803898A MX 9803898 A MX9803898 A MX 9803898A MX 9803898 A MX9803898 A MX 9803898A MX 9803898 A MX9803898 A MX 9803898A
Authority
MX
Mexico
Prior art keywords
amino
product
biomolecule
reactive
aging
Prior art date
Application number
MX9803898A
Other languages
English (en)
Inventor
Anthony Cerami
Yousef Al-Bed
Richard J Bucala
Peter C Ulrich
Original Assignee
Picower Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Inst Med Res filed Critical Picower Inst Med Res
Publication of MX9803898A publication Critical patent/MX9803898A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion se refiere a composiciones y métodos para inhibir el envejecimiento de aminoácidos, péptidos, proteínas y biomoléculas que contienen amino; en consecuencia, se describe una composicion que comprende un agente o compuesto capaz de reaccionar con la porcion glucosilo-amino del producto de glucosilacion inicial (también conocido como el producto de Amadori o el producto de Heyns) formado mediante la reaccion de glucosa, u otros azucares reactivos, con un péptido, proteína o biomolécula que contiene amino, estabilizando así este producto de glucosilacion inicial y evitando su reaccion adicional para formar productos finales de glucosilacion avanzada que contienen carbonilo de cadena abierta; los agentes adecuados pueden contener un grupo aldehído reactivo; un agente que se prefiere es el acetaldehído; el método comprende poner en contacto a la biomolécula objetivo con la composicion; los compuestos de esta manera obtenidos se representan por la formula (VI) y (VIII) en donde R es un residuo de una biomolécula que contiene amino, tal como un péptido, y CH2R' es el residuo del grupo aldehído reactivo; se contemplan ambas aplicaciones industriales y terapéuticas para la invencion, ya que se puede tratar la pudricion de los alimentos y el envejecimiento de la proteína animal.
MX9803898A 1995-11-15 1998-05-15 Metodo y mejorado y agentes para inhibir el envejecimiento de proteina. MX9803898A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US675295P 1995-11-15 1995-11-15

Publications (1)

Publication Number Publication Date
MX9803898A true MX9803898A (es) 1998-09-30

Family

ID=21722402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803898A MX9803898A (es) 1995-11-15 1998-05-15 Metodo y mejorado y agentes para inhibir el envejecimiento de proteina.

Country Status (8)

Country Link
US (1) US5770571A (es)
EP (1) EP0861260A1 (es)
JP (1) JP2000509364A (es)
AU (1) AU723012B2 (es)
CA (1) CA2237565A1 (es)
MX (1) MX9803898A (es)
WO (1) WO1997018223A1 (es)
ZA (1) ZA969617B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796278B1 (fr) * 1999-07-16 2002-05-03 Oreal Utilisation d'au moins un hydroxystilbene comme agent anti-glycation
JP6370094B2 (ja) * 2013-05-08 2018-08-08 第一三共ヘルスケア株式会社 肌の黄ばみを抑制するための組成物
CN103349356B (zh) * 2013-06-19 2016-10-05 河南中烟工业有限责任公司 烟用增香保润剂1-l-亮氨酸-1-脱氧-d-果糖及其制备方法
LU92277B1 (fr) 2013-09-11 2015-03-12 Joventis Sa Composé cosmétique
CN104267118B (zh) * 2014-09-19 2016-10-19 国家烟草质量监督检验中心 一种卷烟主流烟气中羰基化合物的测定方法
CN106822070A (zh) * 2017-01-22 2017-06-13 新乡医学院 一种治疗动脉粥样硬化的药物组合物与应用
CN112920238B (zh) * 2021-01-27 2022-09-30 河南农业大学 一种糖胺类Amadori衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629692A (en) * 1982-12-06 1986-12-16 Miles Laboratories, Inc. Immunoassay for nonenzymatically glucosylated proteins and protein fragments an index of glycemia
US5218001A (en) * 1984-03-19 1993-06-08 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
CH674918A5 (es) * 1988-05-06 1990-08-15 Nestle Sa
US5252188A (en) * 1990-03-26 1993-10-12 Red Arrow Products Company, Inc. Process for producing hydroxyacetaldehyde
DE4202184A1 (de) * 1992-01-28 1993-07-29 Hoechst Ag Substituierte salicylaldehyde zur behandlung von krankheiten

Also Published As

Publication number Publication date
AU1054397A (en) 1997-06-05
ZA969617B (en) 1998-02-19
CA2237565A1 (en) 1997-05-22
WO1997018223A1 (en) 1997-05-22
EP0861260A1 (en) 1998-09-02
JP2000509364A (ja) 2000-07-25
US5770571A (en) 1998-06-23
AU723012B2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
EP0222313A3 (en) Method and agents for inhibiting protein aging
WO1993014750A3 (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
EP0316852A3 (en) Inhibitors of nonenzymatic cross-linking
EP3912642B1 (en) Modified antibody, antibody-conjugate and process for the preparation thereof
Oda et al. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain.
US7193034B2 (en) Synthetic peptides, conjugation reagents and methods
Ahmed et al. Oxidative degradation of glucose adducts to protein. Formation of 3-(N epsilon-lysino)-lactic acid from model compounds and glycated proteins.
DE69620253D1 (en) N-acylaminoalkylhydrazinecarboximidamide
Macmillan et al. Shifting native chemical ligation into reverse through N→ S acyl transfer
MX9803898A (es) Metodo y mejorado y agentes para inhibir el envejecimiento de proteina.
EP0327919A3 (en) Method and agents for preventing staining of teeth
WO2004101597A2 (en) Methods for the reduction of disulfide bonds
HAMAZUME et al. Positions of disulfide bonds in riboflavin protein of hen egg white
EP0657520B9 (en) Antioxidant
Bezouška et al. RETRACTED: NKR-P1A Protein, an Activating Receptor of Rat Natural Killer Cells, Binds to the Chitobiose Core of Uncompletely Glycosylated N-linked Glycans, and to Linear Chitooligomers
Strömqvist et al. Glycosylation of extracellular superoxide dismutase studied by high-performance liquid chromatography and mass spectrometry
Offord The possible use of cyanogen bromide fragments in the semisynthesis of proteins and polypeptides.
FLAHAUT et al. Glycosylation pattern of human inter-α-inhibitor heavy chains
Rose et al. Human interleukin-5 expressed in Escherichia coli has N-terminal modifications
Kawakishi et al. Biomimic Oxidation of Glycated Protein and Amadori
野村幸汰 Homogeneous Glycoprotein Synthesis Utilizing
Feibush et al. Oxidation of the N-terminal gly-residue of peptides: stress study of pexiganan acetate in a drug formulation
Towatari et al. The structures of asparagine‐linked oligosaccharides of rat liver cathepsin L reflect the substrate specificity of lysosomal α‐mannosidase
Coddeville et al. Characterization of sheep hemopexin glycovariants
Zel'tser et al. Use of Sephadex LH-20 for solid-phase synthesis of oxytocin